"I need to reiterate that at this time the risk of serious disease and death from Covid-19, if we experience a severe outbreak, especially among older Australians and those with serious health conditions, is far greater than the very small potential risk of a very rare clotting disorder associated with the vaccine", Kidd said.
However, Australia's Therapeutic Goods Administration and the European Medicines Agency continue to back the rollout of the AstraZeneca vaccine.
Amid growing reports of rare blood clots possibly linked to the AstraZeneca shot, the U.K.'s health regulator said the benefits of the shot continue to outweigh the risks.
In total, MHRA said had identified 30 cases of rare blood clot events out of 18.1 million AstraZeneca doses administered up to and including March 24.
Concerns over the AstraZeneca vaccine have already prompted some countries including Canada, France, Germany and the Netherlands to restrict its use to older people.More news: Statement from Warden Bob Crate on provincial shutdown — RELEASE
Germany restricted the use of the shot to people over 60 years of age, France has limited its use to those over 55.
The World Health Organisation has also urged countries to continue using the jab.
Britain, where the vaccine was developed with the University of Oxford, has been one of the countries worst-hit by coronavirus with almost 127,000 dead.
But the regulator said the benefits of the vaccine in preventing coronavirus outweigh any risks and it urged the public to continue coming forward for the jab.
Adam Finn, a professor of pediatrics at the University of Bristol, said the "extreme rarity" of the blood-clotting events in the context of the millions of jabs administered in the United Kingdom makes the decision very straightforward.More news: Queensland Covid cluster's missing link finally found
More than 31 million people have received a first coronavirus vaccination dose in Britain, which is using both the AstraZeneca vaccine and the BioNTech-Pfizer version.
The cases include 22 reports of cerebral venous sinus thrombosis (CVST) and eight other thrombosis events with low platelets.
Elaborating, Dr Noor Azmi, who is also the Bagan Serai Member of Parliament, said the AstraZeneca vaccine, produced from a viral vector by placing weak virus with protein to stimulate the human body similar to other vaccines, was expected to arrive in Malaysia in May.
The Minister wrote in a letter to Parliament that he took this decision pending a further judgment by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency.
In a statement on Friday, the Australian Technical Advisory Group on Immunisation said, "There is not a higher overall rate of relatively common types of blood clots (.) reported after COVID-19 vaccination".More news: US Capitol On Lockdown After Vehicle Rams 2 Officials, Driver Dead
The UK in June 2020 ordered 100 million doses of the Oxford-AstraZeneca vaccine and supported its development.